linjc16/ctgov huggingface dataset:
CRF - Nociceptin Receptor Interactions

Study Overview
=================
Brief Summary
-----------------
To determine if [C-11]NOP-1A receptor binding (VT) can be altered by an intravenous hydrocortisone (cortisol) challenge through CRF-NOP interactions

Detailed Description
-----------------
Examines changes in [C-11]NOP-1A pharmacokinetics caused by an intravenous hydrocortisone challenge (1 mg/kg)

Official Title
-----------------
In Vivo Imaging of Corticotropin-releasing Factor - Nociceptin Receptor Interactions

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Hydrocortisone
* Radiation: [C-11]NOP-1A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females between 18 and 40 years old Exclusion Criteria: Current DSM-5 psychiatric disorders Binge drinking as defined in NIAAA criteria in the past month Recreational abuse of opiates, sedative-hypnotics, cocaine, amphetamines, MDMA, and PCP, as well as cannabis use Currently on any prescription medical or psychotropic medication; Current or past severe medical, endocrine, cardiovascular, immunological or neurological illnesses Currently pregnant or breast-feeding; History of radioactivity exposure via prior nuclear medicine studies or occupational exposure in past twelve months Metallic objects in the body that are contraindicated for MRI; First-degree relative with psychosis or mood disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Interventional Model Description: Baseline [C-11]NOP-1A scan Post-hydrocortisone [C-11]NOP-1A scan
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: [C-11]NOP-1A PET Scan conditions<br>Baseline condition and Post-hydrocortisone (1 mg/Kg, intravenous) condition | Drug: Hydrocortisone<br> <br> Radiation: [C-11]NOP-1A<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| [C-11]NOP-1A Volume of Distribution Expressed Relative to Total Plasma Concentration | VT is the volume of distribution expressed relative to total plasma concentration. This is defined consistent with that reported in Consensus nomenclature for in vivo imaging of reversibly binding radioligands (Reference: J Cereb Blood Flow Metab 2007 Sep;27(9):1533-9. doi: 10.1038/sj.jcbfm.9600493) | Baseline and 3.5 hours post-hydrocortisone |
Impact of CT on Diagnosis of Acute Appendicitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether computed tomography is reliable investigation in the diagnosis of acute appendicitis.

Detailed Description
-----------------
The aim of this study is to evaluate CT scan validity for the diagnosis of acute appendicitis. compare the difference in evaluation of CT-scan result between radiologist on call and consultant radiologist with CT experience. illustrate difficulties associated with practical implementation of CT-scan in relation to other activities in radiology department and O.R. (logical & organizational). illustrate patients experiences about the study (pain, discomfort & other information

Official Title
-----------------
The Impact Of Computed Tomography On The Diagnoses Of Acute Appendicitis

Conditions
-----------------
Acute Appendicitis

Intervention / Treatment
-----------------
* Other: CT scanning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have been admitted and diagnosed as having acute appendicitis Exclusion Criteria: Patients under the age of 18 years. Pregnancy. Uncooperative patients (senile dementia, mentally ill). Not speaking Danish. Does not wish to participate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with acute appendicitis<br>Patients who have been clinically diagnosed to have acute appendicitis | Other: CT scanning<br>* CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.<br>* Other names: CT scanning of the abdomen;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute appendicitis, diagnosis, computed tomography
Feasability Test of a Handset Device to Detect Levels of Sedation and Loss of Consciousness

Study Overview
=================
Brief Summary
-----------------
Sedation is often administered to relieve anxiety and discomfort during uncomfortable procedures in elderly patients. Patient control of sedation offers many potential benefits for patients and healthcare professionals, including improved safety and patient satisfaction. The investigators overall goal is to develop a patient controlled intravenous sedation system that is effective but very safe for the patient, and requires minimal supervision by a doctor or nurse. To fulfill these criteria, a sedation system should incorporate fail-safe safety mechanisms. A key safety-critical component is a method of objectively assessing the degree of sedation of the patient, and of preventing him from self-administering unsafe doses of the sedative drug. The investigators have designed a new sedation system that uses a measure of the speed of response of the patient to a defined non-noxious stimulus to determine whether or not it is safe to allow him to self-administer further levels of sedation. Before being able to execute a volunteer study in order to determine a rational selection of optimal threshold response time, a feasibility test on the handset device is required.

Official Title
-----------------
Feasibility Test of a Handset Device to Detect Sedation Levels and Loss of Consciousness During Propofol Administration

Conditions
-----------------
Conscious Sedation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 50-72 years Exclusion Criteria: volunteer refusal patient age >72 years significant cardiovascular or respiratory disease latex allergy

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response times | Response time between non-noxious stimulus and activation of handset device | Continuously shortly before (baseline) | 
| response time | Response time between non-noxious stimulus and activation of handset device | during induction of anesthesia | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sedation
Safety and Tolerability of ACU-4429

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and tolerability of a new investigational drug (ACU-4429) in healthy human volunteers.

Official Title
-----------------
A Single Center, Randomized, Double-Masked, Dose-Escalating, Placebo-Controlled Study of the Safety and Tolerability ACU-4429 in Healthy Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: ACU-4429
* Drug: matching placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Is male or female with age ≥ 55 and ≤ 80 years at the time of consent Is healthy as determined by medical history and physical examination Exclusion Criteria: Is receiving or has recently received treatment with a medication disallowed per the protocol

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>ACU-4429 | Drug: ACU-4429<br>* administered as a single dose, orally<br>|
| Placebo Comparator: 2<br>matching placebo | Drug: matching placebo<br>* administered as a single dose, orally<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability |  | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics |  | 2 days |
Cytokines, POD, Health Status, Older Hip Fracture

Study Overview
=================
Brief Summary
-----------------
An investigation of the change in inflammation marker levels across hip fracture surgery and an exploration of any association with change in self reported health status and incidence of postoperative delirium

Official Title
-----------------
Perioperative Cytokines, Postoperative Delirium and Health Status in Older People Undergoing Hip Fracture Surgery - a Pilot Study

Conditions
-----------------
Postoperative Delirium, Hip Fracture Surgery, Older People

Intervention / Treatment
-----------------
* Procedure: Hip fracture Surgery (Primary)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 65 years old Admitted for primary hip fracture surgery Exclusion Criteria: Preoperative cognitive impairment History of neurosurgery, neurologic diseases or head trauma Current systemic bacterial or viral infection Complex or multiple injuries

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br>People age 65 years and older undergoing primary hip fracture surgery | Procedure: Hip fracture Surgery (Primary)<br>* Surgery for primary hip fracture requiring general or neuro-axial anaesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cytokine dynamics | Difference preoperative serum cytokine levels and postoperative serum cytokine levels in pg/mL. | 2 days | 
| Incidence of postoperative delirium | Assessment for presence or absence of delirium during the post operative period. | 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self reported health related quality of Life | Assessed preoperatively and again at approximately 120 days after surgery using the EuroQol Five Dimension Five level (EQ-5D-5L) tool. The tool assesses on five aspects of health (Dimensions) and each dimension has five possible levels. The tool also has a visual analogue scale ranging from 0 (poorest) to 100 (best health) | 120 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postoperative delirium, Older people, Cytokines, Self-reported Health Status
Platelet Antisedimentation Rate and Multiplate Exams in Patients on Antiplatelet Therapy and Controls

Study Overview
=================
Brief Summary
-----------------
To search for simple laboratory methods selecting patients with low/non-responsiveness to P2Y12 receptor antagonists.

Official Title
-----------------
Platelet Antisedimentation Rate and Multiplate ex Vivo Examinations in Cerebrovascular Patients Treated With Antiplatelet Therapy and Healthy Controls

Conditions
-----------------
Cerebrovascular Disorders, Platelet Refractoriness, Platelet Aggregation, Spontaneous

Intervention / Treatment
-----------------
* Other: Platelet function test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent Exclusion Criteria: Declined informed consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Platelet function test in patients<br>Platelet function test in patients on antiplatelet therapy | Other: Platelet function test<br>* Ex vivo platelet aggregation analysis by Multiplate aggregometer<br>|
| Platelet function test in healthy<br>Platelet function test in healthy subjects | Other: Platelet function test<br>* Ex vivo platelet aggregation analysis by Multiplate aggregometer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major cerebrovascular event |  | 1 year |
Parameter Changes in Functional Electrical Stimulation

Study Overview
=================
Brief Summary
-----------------
This study aims to look at how changes to a person's functional electrical stimulation might change how they walk. Functional electrical stimulation (FES) is commonly used to help people with foot drop from upper motor neurone conditions such as stroke or multiple sclerosis. This group of people have muscle weakness which makes it difficult to lift the foot, which causes trips and falls. FES reduces foot drop by using a portable device to apply short electrical pulses to the nerve which lifts the foot. The FES device stimulates this nerve only during the swing phase, when the foot is off the floor. Typically this is achieved by using a foot-switch, which detects when the heel leaves the floor. Stimulation begins a short interval of time after the heel leaves the floor, ramps up from zero to set stimulation for the individual, and at another period of time after the heel hits the floor, stimulation ramps down from set amount to zero. There are four time intervals described here which can be varied by the clinician on the device:- Delay (the time between heel lift and the start of stimulation) Ramp up (the time for stimulation to reach full strength) Extension (the time between heel strike and the ramp down) Ramp down (the time for stimulation to reach zero from full strength) These intervals are usually set by experienced clinicians using a qualitative assessment of the patient's walking and trial-and-error. A literature review has found no published studies which compare walking with different timing. This knowledge would be useful for clinicians, who could use this information as a starting point in finding the best timing parameters for each patient.

Conditions
-----------------
Gait Disorders, Neurologic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Upper motor neurone lesion causing foot drop Currently use single-channel Odstock Medical ODFS functional electrical stimulator Age 18 or older Attending Leeds FES Service follow-up clinics Exclusion Criteria: • FES user for less than three months Lower limb prosthesis Cannot walk 5m with walking aids Cannot walk twenty 5m walks within a three-hour period Use FES less than once per week

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Functional Electrical Stimulation (FES) users<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gait analysis will be measured according to routine protocol | Gait analysis will measured in accordance with the Plug-In-Gait model guide. This measures 16 points on the subjects left and right leg. | Gait will be assessed over one visit of three hours. |
Prevention of Postpartum Depression in Low-Income Women

Study Overview
=================
Brief Summary
-----------------
This study will determine whether a prevention program reduces the incidence of postpartum depression in pregnant women who receive public assistance and are at risk for postpartum depression.

Detailed Description
-----------------
The impact of major depression in the postpartum period is profound, with considerable emotional pain for the new mother as well as disturbances in infant development. Unfortunately, few preventive interventions have been developed or systematically tested to reduce the risk of postpartum depression. An area of even greater neglect is the development of such an intervention for financially disadvantaged women who are at high risk for postpartum depression and for the disturbances associated with postpartum depression. This study will develop a psychosocial intervention for financially disadvantaged pregnant women at risk for postpartum depression. Participants are randomly assigned to receive either the Life at Home with a New Baby intervention or care as usual. Women who receive the intervention join a counseling group in which information about mother-baby relationships is shared. This information is reinforced with a follow-up booster session after the infant is born. Participants are assessed at baseline, after the booster session (for the intervention condition) or after 2 weeks postdelivery (for the care as usual condition), and at 3 months postpartum. Depression levels and social adjustment are measured at baseline and 2 weeks after delivery. Functional status is also measured. A self-report questionnaire is completed by the mothers to measure parental distress, parent/child dysfunctional behavior, and difficult child interactions. At 3 months postpartum, a brief standardized interview is used to assess the presence of a depressive disorder.

Official Title
-----------------
Depression Intervention for Poor Pregnant Women

Conditions
-----------------
Depression, Postpartum

Intervention / Treatment
-----------------
* Behavioral: Survival Skills for Moms with New Babies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Receive public assistance At risk for postpartum depression Pregnant women between 23-32 weeks gestation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Survival Skills for Moms with New Babies|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effect of Pneumoperitoneum on the Continuous and Non-invasive Hemoglobin Monitoring

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to investigate the effect of pneumoperitoneum on the continuous and non-invasive hemoglobin monitoring during laparoscopic gastrectomy

Official Title
-----------------
Effect of Pneumoperitoneum on the Continuous and Non-invasive Hemoglobin Monitoring for Laparoscopic Gastrectomy: a Randomized Controlled Study

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Other: High end-tidal CO2
* Other: Low CO2 group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Laparoscopic gastrectomy under general anesthesia Exclusion Criteria: atypical hemoglobin disease, infective state, cardiovascular disease, peripheral vascular disease

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High CO2 group<br>end tidal CO2 : 40-45 mmHg | Other: High end-tidal CO2<br>* maintaining of end-tidal CO2 with the range of 40-45 mmHg<br>|
| Placebo Comparator: Low CO2 group<br>end tidal CO2 : 30-35 mmHg | Other: Low CO2 group<br>* maintaining of end-tidal CO2 with the range of 30-35 mmHg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| difference between SpHb value and SaHb value (SpHb - SaHb) | SpHb value is measured by co-oxymetry, and SaHb value is measured by blood sampling. | from the start of anesthesia to the end of anesthesia, an average 2 hours |